A recent study reveals that people who discontinue popular GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise programs.
Research printed in a leading health publication demonstrates that while overweight people can lose a large proportion of their total mass while undergoing treatment, the mass is regained at an estimated rate of 0.8 kg per month after stopping.
"People using these drugs need to be aware of the potential of fast rebound weight gain when the therapy ends," warns lead investigator Dr. Susan Jebb.
This pace of regain implies a return to pre-treatment weight within about 18 months.
Analyzing Therapies
The analysis, which looked at dozens of trials involving over 9,000 of patients, contrasted the effects of the injectable medications with other pills.
The team emphasize that people who shed pounds through dieting generally experience a more gradual creep back—approximately 100 grams monthly—after stopping.
Explaining the Fast Rebound
Experts suggest the way of the injections accounts for the amplified weight return.
The injections mimic a body's own chemical called GLP-1, which helps regulate appetite.
"Artificially providing GLP-1 concentrations several times higher than normal may cause the body to generate a reduced amount of its own natural GLP-1, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics expert.
"Stopping of this hormone supplement leads to hunger is unsuppressed, making overeating far more likely."
An Ongoing Issue?
The NHS recommend the jabs for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Professionals argue that, considering the likelihood of weight regain, the treatment should be considered life-long.
This view is supported by pharmaceutical companies, who say that the findings "highlight the persistent nature of obesity," comparing it to managing conditions like diabetes.
Patient Accounts
Users who have stopped the jabs explain a powerful resurgence of appetite.
"It was like a trigger activating and I was suddenly ravenous," described an individual.
The struggle is compounded if patients have not established lasting dietary or behavioural changes during therapy.
Growing Use
Survey data suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with demand continuing to grow.
- Adoption is more common among females compared to men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion obtain the medications through private healthcare rather than public health services.
Finally, researchers caution that while the jabs are powerful tools for weight loss, they are not a magic fix and lasting health benefits hinges on ongoing behavioural management.
